浙江成立重大疾病研究中心

2017-10-21 佚名 健康报

从浙江省卫生计生委获悉,为加强重大疾病技术攻关,浙江省成立胃癌、肺癌、子宫恶性肿瘤3个重大疾病诊治技术研究中心,分别由浙江大学医学院附属第二医院、浙江省肿瘤医院、浙江大学医学院附属妇产科医院牵头,会同省内外优势医院,组建专家团队。

从浙江省卫生计生委获悉,为加强重大疾病技术攻关,浙江省成立胃癌肺癌、子宫恶性肿瘤3个重大疾病诊治技术研究中心,分别由浙江大学医学院附属第二医院、浙江省肿瘤医院、浙江大学医学院附属妇产科医院牵头,会同省内外优势医院,组建专家团队。

今年9月,浙江省卫生计生委、财政厅印发《浙江省重大疾病诊治技术研究中心建设与管理试行办法的通知》,浙江省财政对每个中心资助500万元,相关单位配套后,每个中心总建设经费将超过1000万元。

浙江省重大疾病技术研究中心启动建设的3年内,将依托团队基本建成跨部门、跨地区的临床诊治技术协作平台,并形成临床合作共享机制。这将推动重大疾病技术的相关先进技术走出城市大医院,辐射推广至全省,使城乡患者同时受益。

浙江省卫生计生委、财政厅对3个中心的评估与验收将打破“唯课题”“唯论文”,患者的临床获益效果将成为今后的主要考核依据。根据规划,胃癌、肺癌、子宫恶性肿瘤技术研究中心将使各期患者的5年平均生存率提升5%到10%。

根据规划,继胃癌、肺癌、子宫恶性肿瘤3个重大疾病诊治技术研究中心之后,浙江省还将继续建设一批在全国具有领先地位和影响力的卫生健康科技创新平台,实现重大疾病优势领域诊治水平大幅提升,持续改善和提高居民健康水平。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2070421, encodeId=dea020e0421c8, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Sep 16 10:13:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628942, encodeId=c08216289420d, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Oct 23 14:13:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255037, encodeId=df9725503eb0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun Oct 22 08:06:31 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255000, encodeId=9bdf2550005b, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 22 07:09:14 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254985, encodeId=85302549859c, content=非常好.更好为患者服务, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Oct 22 06:06:35 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254980, encodeId=71fa25498052, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:40 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254970, encodeId=12b82549e096, content=经费很充足啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Oct 22 00:55:19 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2070421, encodeId=dea020e0421c8, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Sep 16 10:13:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628942, encodeId=c08216289420d, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Oct 23 14:13:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255037, encodeId=df9725503eb0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun Oct 22 08:06:31 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255000, encodeId=9bdf2550005b, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 22 07:09:14 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254985, encodeId=85302549859c, content=非常好.更好为患者服务, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Oct 22 06:06:35 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254980, encodeId=71fa25498052, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:40 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254970, encodeId=12b82549e096, content=经费很充足啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Oct 22 00:55:19 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2070421, encodeId=dea020e0421c8, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Sep 16 10:13:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628942, encodeId=c08216289420d, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Oct 23 14:13:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255037, encodeId=df9725503eb0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun Oct 22 08:06:31 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255000, encodeId=9bdf2550005b, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 22 07:09:14 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254985, encodeId=85302549859c, content=非常好.更好为患者服务, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Oct 22 06:06:35 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254980, encodeId=71fa25498052, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:40 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254970, encodeId=12b82549e096, content=经费很充足啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Oct 22 00:55:19 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-10-22 杨利洪

    学习了提高了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2070421, encodeId=dea020e0421c8, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Sep 16 10:13:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628942, encodeId=c08216289420d, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Oct 23 14:13:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255037, encodeId=df9725503eb0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun Oct 22 08:06:31 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255000, encodeId=9bdf2550005b, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 22 07:09:14 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254985, encodeId=85302549859c, content=非常好.更好为患者服务, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Oct 22 06:06:35 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254980, encodeId=71fa25498052, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:40 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254970, encodeId=12b82549e096, content=经费很充足啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Oct 22 00:55:19 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-10-22 1dd8c52fm63(暂无匿称)

    了解了解.继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2070421, encodeId=dea020e0421c8, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Sep 16 10:13:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628942, encodeId=c08216289420d, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Oct 23 14:13:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255037, encodeId=df9725503eb0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun Oct 22 08:06:31 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255000, encodeId=9bdf2550005b, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 22 07:09:14 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254985, encodeId=85302549859c, content=非常好.更好为患者服务, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Oct 22 06:06:35 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254980, encodeId=71fa25498052, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:40 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254970, encodeId=12b82549e096, content=经费很充足啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Oct 22 00:55:19 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-10-22 swfzhanggui

    非常好.更好为患者服务

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2070421, encodeId=dea020e0421c8, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Sep 16 10:13:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628942, encodeId=c08216289420d, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Oct 23 14:13:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255037, encodeId=df9725503eb0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun Oct 22 08:06:31 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255000, encodeId=9bdf2550005b, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 22 07:09:14 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254985, encodeId=85302549859c, content=非常好.更好为患者服务, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Oct 22 06:06:35 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254980, encodeId=71fa25498052, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:40 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254970, encodeId=12b82549e096, content=经费很充足啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Oct 22 00:55:19 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-10-22 yjs木玉

    好好好好好好好好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2070421, encodeId=dea020e0421c8, content=<a href='/topic/show?id=f30de0713e1' target=_blank style='color:#2F92EE;'>#疾病研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70713, encryptionId=f30de0713e1, topicName=疾病研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Sep 16 10:13:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628942, encodeId=c08216289420d, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Mon Oct 23 14:13:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255037, encodeId=df9725503eb0, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sun Oct 22 08:06:31 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255000, encodeId=9bdf2550005b, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Oct 22 07:09:14 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254985, encodeId=85302549859c, content=非常好.更好为患者服务, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Sun Oct 22 06:06:35 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254980, encodeId=71fa25498052, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:40 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254970, encodeId=12b82549e096, content=经费很充足啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Sun Oct 22 00:55:19 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-10-22 lyh994

    经费很充足啊

    0

相关资讯

新版医保药品目录公布 关注儿童用药、重大疾病用药

人力资源和社会保障部23日公布了2017年版国家基本医疗保险、工伤保险和生育保险药品目录。人社部相关负责人表示,新版目录扩大了基本医疗保险用药保障范围,有利于减轻参保人员目录外药品费用负担,也将对临床用药技术进步产生推动作用。

32岁的年轻人,向你们致敬!扎克伯格夫妇今日宣布捐赠30亿美元攻克重大疾病

北京时间今日凌晨2点,扎克伯格夫妇宣布,Chan Zuckerberg Initiative将在未来10年内投入30亿美元的巨额资金,资助科学家们攻克世界上最主要的疾病。他们期望在下一代人成长的过程中,能够更少受到疾病的影响,从而过上高质量的生活。扎克伯格夫妇计划在旧金山创立一个生物中心,让科学家们能集中推进项目的进行。这个Initiative的科学委员会成员包括NIH负责人Francis Col

美妙的谜团——为何这些重大疾病正逐渐式微

很多人可能没有注意到这样的一个现象:尽管肥胖症、糖尿病等“富贵病”的正逐渐侵蚀着人类的健康,但结直肠癌、心脏病、精神分裂症等其他主要疾病的发病率却在发达国家的呈下降趋势。或许,你对此并不感到奇怪,因为医学在不断进步。然而,针对这些疾病诊断和治疗手段的提高却不足以解释这一现象。 “我们很容易能找到一些有趣而且有说服力的解释,”哈佛大学的医学史专家David S. Jones博士说道:“但是问

Lancet Respir Med:重大疾病幸存者的心理健康状况

背景:重大疾病与认知损害之间的关联已经得到认可,但重症监护幸存者的身心健康状况尚未得到充分认识。 我们的目的是在此组中评估年龄及谵妄持续时间与身心健康状况之间的关联。方法:在这项前瞻性、多中心队列研究中,我们纳入了曾在美国田纳西州纳什维尔内科或外科重症监护病房接受治疗的呼吸衰竭或休克患者。 我们取得了基线人口统计学数据和住院变量,并通过测量抑郁症(白氏抑郁症量表 II)、创伤后应激障碍(

JAMA:对医院进行经济处罚与患者再入院率之间相关性的研究

减少医院再入院计划(HRRP)是指如果急性心肌梗死(AMI)、心力衰竭(HF)和肺炎的再入院率过多,该计划将惩罚医院,在宣布该计划之后,再入院率下降。为了比较上述目标条件患者和非目标条件患者的再入院率趋势,按医院处罚状态分层后,一项发表在JAMA杂志上的文章进行了研究分析。首先研究者们采用回顾性队列研究了2214个受惩罚医院和1283个非受处罚医院中自2008年1月1日至2015年6月30日期间,